Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluconazole

FDA-approved product (tablet, oral), marketed as Diflucan, Diflucan In Dextrose 5% In Plastic Container, Diflucan In Sodium Chloride 0.9% and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis
  • Cryptococcal meningitis
  • Urinary tract infection
  • Vulvovaginal candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives; Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC15; WHO ATC J02AC01; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

    NCT00002040

    Registered record
    Registry ID
    NCT00002040
    Conditions
    Meningitis, Cryptococcal; HIV Infections
    Interventions
    Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Cryptococcal; HIV Infections
    InterventionFluconazole
    PhaseNot applicable
    Registry statusCompleted

  • A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

    NCT00002068

    Registered record
    Registry ID
    NCT00002068
    Conditions
    Meningitis, Cryptococcal; HIV Infections
    Interventions
    Fluconazole; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Cryptococcal; HIV Infections
    InterventionFluconazole; Amphotericin B
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

    NCT00002306

    Registered record
    Registry ID
    NCT00002306
    Conditions
    Meningitis, Cryptococcal; HIV Infections
    Interventions
    Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Cryptococcal; HIV Infections
    InterventionFluconazole
    PhaseNot applicable
    Registry statusCompleted

  • A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

    NCT00002399

    Registered record
    Registry ID
    NCT00002399
    Conditions
    Candidiasis, Oral; HIV Infections
    Interventions
    Posaconazole; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Oral; HIV Infections
    InterventionPosaconazole; Fluconazole
    PhasePhase 2
    Registry statusCompleted

  • Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

    NCT00005920

    Registered record
    Registry ID
    NCT00005920
    Conditions
    Candidiasis, Oral; HIV Infections
    Interventions
    L-743,872
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Oral; HIV Infections
    InterventionL-743,872
    PhasePhase 2
    Registry statusTerminated